FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
ReGenesys is a biopharmaceutical company focused on the research and development of stem cell based therapies. ReGenesys is a wholly-owned subsidiary of Athersys, a publicly held biotechnology company located in Cleveland, Ohio.
ReGenesys is a wholly-owned subsidiary of Athersys, a publicly held biotechnology company located in Cleveland, Ohio (NASDAQ: ATHX). The company has two core business units. One is based on drug discovery / functional genomics screening, and has developed a lead compound for treatment of obesity that is now in Phase II clinical study. The second platform is a stem cell therapeutic opportunity, based on pluripotent stem cells isolated from bone marrow. The company has established master cell banks and successfully produced a cGMP cell product by FDA guidelines. ReGenesys is focused on establishing additional stem cell banks and European manufacturing capability.
The company's stem cell product, MultiStem™, is a cryopreserved allogeneic cell product. Currently, a Phase I clinical trial on AMI has been executed and 2 trials are open; one for the treatment of graft versus host disease (aGVHD) in bone marrow transplantation, one for treatment of Stroke.
The company is planning new trials for cGVHD, support in organ transplantation and inflammatory bowel diseases.
MultiStem™ – a cryopreserved allogeneic cell product
Regenerative medicine (AMI/GVDH/Stroke)